myTomorrows is an independent, globally operating organization based in the Netherlands. We provide patients with unmet medical needs, and their doctors, information about treatment options worldwide and facilitate access to medicines in development.
Our goal is to ensure that patients and doctors don’t miss out on treatment options due to lack of information, understanding and administrative hurdles.
Medicines in development
Out of approximately 10.000 known diseases, only 5% have registered treatments available. Drug development aims to address this need for more treatments, but it can take more than 12 years for a medicine to be authorized and go to market. This leaves many doctors and their patients without access to treatment options that already show hopeful results during this period.
Early access or compassionate use programs are intended to help fill this gap, but in reality there are many hurdles to identify and access medicines in development making them practically inaccessible.
Up to date information
The world of medicines in development is vast and complicated: information is fragmented and written in highly specific medical language. It’s difficult for a patient to understand and very time consuming for a doctor to identify possible treatment options for unmet medical needs.
To make this easier for patients and doctors, we have built an extensive Knowledge Base with up-to-date information on medicines in development available around the world, clinical trials and scientific publications. We have created separate entry points for patients and doctors so that patients are not overwhelmed with medical jargon.
Patient and doctors in control
myTomorrows does not provide any form of diagnostic services. We do not give suggestions or recommendations on treatment options.
We provide information about potentially suitable treatment options with medicines in development we can find around the globe. Based on that information patients and their doctors decide together if they want to try getting access to such a pre-approval medicine.
myTomorrows' Business Model
myTomorrows is a business, and to support its mission to provide better access for patients to medicines it does require revenue. When a medicine is reimbursed for a patient, the manufacturer of the medicine pays a fee to myTomorrows for our ongoing regulatory, pharmacovigilance and wholesaler delivery support.
In line with the myTomorrows mission of reducing barriers to early access, with many companies myTomorrows agrees to receive reimbursement for today’s early access services in the future, after the medicine has actually been commercialized.
Search for possible treatment options in our
Clinical Trials and Early Access Programs database
About the founder
myTomorrows was founded in 2012 by Ronald Brus, a doctor who built a career in the pharmaceutical industry, serving as CEO of several large pharmaceutical companies. When his father was diagnosed with lung cancer he experienced firsthand how difficult it was to get access to drugs in development, despite his connections within the industry, knowledge and means.
Our team is driven, caring, and determined. Many of us have personal experience with serious illness, so we understand the desire to know about all available options when diagnosed with a medical condition.
While we come from different backgrounds and disciplines, each member of our team contributes expertise...